caffeine has been researched along with fluvoxamine in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (30.00) | 18.2507 |
| 2000's | 9 (30.00) | 29.6817 |
| 2010's | 11 (36.67) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brśen, K; Jeppesen, U; Loft, S; Poulsen, HE | 1 |
| Alm, C; Bertilsson, L; Carrillo, JA; Dahl, ML; Rodríguez, I; Svensson, JO | 1 |
| Brøsen, K; Gram, LF; Jeppesen, U; Loft, S; Poulsen, HE; Vistisen, K | 1 |
| Taylor, D | 1 |
| Herrmann, N; Kalow, W; Naranjo, CA; Ozdemir, V; Reed, K; Sellers, EM; Shulman, RW | 1 |
| Beck, DJ; Bertino, JS; Gotschall, R; Kashuba, AD; Kearns, GL; Kulawy, RW; Leeder, JS; Nafziger, AN; Rocci, ML | 1 |
| Spigset, O | 1 |
| Brøsen, K; Nielsen, TL; Rasmussen, BB | 1 |
| Dahlqvist, R; Hägg, S; Söderström, E; Spigset, O | 1 |
| Kalow, W; Pastrakuljic, A; Roberts, EA; Sy, SK; Tang, BK | 1 |
| Axelsson, S; Dahlqvist, R; Hägg, S; Norström, A; Spigset, O | 1 |
| Eto, S; Matsushita, M; Nakamura, J; Ueda, N; Yoshimura, R | 1 |
| Andersson, K; Bertilsson, L; Carrillo, JA; Christensen, M; Dahl, ML; Mihara, K; Ramos, SI; Tybring, G; Yasui-Furokori, N | 1 |
| Culm-Merdek, KE; Greenblatt, DJ; Harmatz, JS; von Moltke, LL | 1 |
| Fukasawa, T; Inoue, Y; Ishii, G; Otani, K; Suzuki, A; Tateishi, T; Yasui-Furukori, N | 1 |
| Ansermot, N; Baumann, P; Crettol, S; Eap, CB; Harenberg, S; Jaquenoud Sirot, E; Knezevic, B; Morena, GP; Oneda, B | 1 |
| Nakamura, J; Yoshimura, R | 1 |
| Namiki, N; Tanaka, S; Uchida, S | 1 |
| Hoffmann, M; Li, Y; Liu, L; Palmisano, M; Reyes, J; Wang, X; Zhang, C; Zhou, S | 1 |
| Abe, H; Jamal, M; Kawahara, S; Kimura, S; Kinoshita, H; Kumihashi, M; Miyatake, N; Takei, S; Tanaka, E; Yamashita, T | 1 |
2 review(s) available for caffeine and fluvoxamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacokinetic interactions involving clozapine.
Topics: Anti-Bacterial Agents; Anticonvulsants; Antipsychotic Agents; Caffeine; Cimetidine; Clozapine; Drug Interactions; Erythromycin; Fluvoxamine; Humans; Risperidone; Selective Serotonin Reuptake Inhibitors | 1997 |
8 trial(s) available for caffeine and fluvoxamine
| Article | Year |
|---|---|
A fluvoxamine-caffeine interaction study.
Topics: Adult; Biotransformation; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Drug Interactions; Fluvoxamine; Half-Life; Humans; Methylation; Reference Values; Selective Serotonin Reuptake Inhibitors | 1996 |
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Caffeine; Chromatography, High Pressure Liquid; Citalopram; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Male; Mephenytoin; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sparteine | 1996 |
Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance.
Topics: Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Drug Interactions; Fluvoxamine; Humans; Male; Selective Serotonin Reuptake Inhibitors; Theophylline | 1999 |
Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Topics: Adrenergic Agents; Adult; Area Under Curve; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2 Inhibitors; Debrisoquin; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Fluvoxamine; Humans; Male; Middle Aged; Omeprazole; Selective Serotonin Reuptake Inhibitors | 2002 |
Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics.
Topics: Area Under Curve; Caffeine; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Cross-Over Studies; Double-Blind Method; Drug Combinations; Drug Interactions; Electroencephalography; Female; Fluvoxamine; Half-Life; Humans; Male; Middle Aged; Psychomotor Performance; Selective Serotonin Reuptake Inhibitors | 2005 |
Effects of caffeine on the kinetics of fluvoxamine and its major metabolite in plasma after a single oral dose of the drug.
Topics: Adult; Amino Acids; Antidepressive Agents, Second-Generation; Area Under Curve; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Double-Blind Method; Fluvoxamine; Half-Life; Humans; Male; Metabolic Clearance Rate | 2006 |
ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Fluvoxamine; Genotype; Humans; Male; Midazolam; Middle Aged; Phenotype; Polymorphism, Genetic; Substrate Specificity; Switzerland; Young Adult | 2009 |
In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.
Topics: Adult; Aged; Area Under Curve; Caffeine; Cigarette Smoking; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inhibitors; Drug Interactions; Fluvoxamine; Half-Life; Healthy Volunteers; Humans; Male; Middle Aged; Thalidomide | 2018 |
20 other study(ies) available for caffeine and fluvoxamine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity.
Topics: Adrenergic Agents; Adult; Caffeine; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Debrisoquin; Female; Fluvoxamine; Humans; Male; Middle Aged; Reference Values; Selective Serotonin Reuptake Inhibitors; Smoking | 1996 |
Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Female; Fluvoxamine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1998 |
Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.
Topics: Acetyltransferases; Adult; Anti-Anxiety Agents; Antitussive Agents; Aryl Hydrocarbon Hydroxylases; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dextromethorphan; Female; Fluvoxamine; Genotype; Humans; Hypnotics and Sedatives; Male; Midazolam; Oxidoreductases, N-Demethylating; Phenotype; Reference Values; Selective Serotonin Reuptake Inhibitors; Time Factors; Xanthine Oxidase | 1998 |
Are adverse drug reactions attributed to fluvoxamine caused by concomitant intake of caffeine?
Topics: Caffeine; Contraindications; Drug Interactions; Fluvoxamine; Humans | 1998 |
Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro.
Topics: Caffeine; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2 Inhibitors; Drug Interactions; Fluvoxamine; Humans; In Vitro Techniques; Microsomes, Liver; Selective Serotonin Reuptake Inhibitors | 1998 |
Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine.
Topics: Aging; Caffeine; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Enzyme Inhibitors; Fluvoxamine; Humans; Isoenzymes; Kinetics; Microsomes, Liver; Models, Statistical; Molecular Probes; Phenacetin; Substrate Specificity | 2001 |
The major fluvoxamine metabolite in urine is formed by CYP2D6.
Topics: Adult; Area Under Curve; Caffeine; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluvoxamine; Humans; Male; Selective Serotonin Reuptake Inhibitors; Smoking | 2001 |
Interaction between fluvoxamine and cotinine or caffeine.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Caffeine; Central Nervous System Stimulants; Cotinine; Cytochrome P-450 CYP1A2; Depressive Disorder, Major; Drug Interactions; Female; Fluvoxamine; Humans; Male; Middle Aged; Smoking | 2002 |
[Effects of smoking and caffeine on pharmacological treatment for patients with schizophrenia and depression].
Topics: Caffeine; Depression; Drug Interactions; Fluvoxamine; Humans; Risperidone; Schizophrenia; Smoking | 2011 |
Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats.
Topics: Animals; Caffeine; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Dextromethorphan; Drug Interactions; Fluconazole; Fluvoxamine; Ketoconazole; Losartan; Male; Midazolam; Omeprazole; Rats, Sprague-Dawley | 2014 |
An autopsy case of BRON
Topics: Autopsy; Caffeine; Chlorpheniramine; Drug Overdose; Eating; Fluvoxamine; Humans; Male | 2023 |